International Society of Microbiota (ISM)
4–5 November 2026
Málaga, Spain
Building a clinical-stage biopharmaceutical company supported by leaders in precision microbiome science and medicine, and a strong syndicate of investors.
Advancing our pipeline of clinic-ready defined live biotherapeutic products, with known mechanisms of action, for immuno-oncology and inflammatory bowel disease.
Leveraging our clinic-led discovery platform to enable precise identification of bacteria linked to patient outcomes and targeting of specific patient populations.